Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
| ▸ | ACACA | Q13085 | 2/20 | 0.41 |
| ▸ | GHSR | Q92847 | 3/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3000428 | 0.96 | F10 (0.58) | F10KDM4EALDH1A1MAPTHPGD | |
| Hydrochloric Acid SCHEMBL4840239 | 0.95 | F10 (0.57) | F10KDM4EALDH1A1MAPTHPGD | |
| Hydrochloric Acid SCHEMBL4841878 | 0.95 | F10 (0.57) | F10KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL6215912 | 0.92 | F10 (0.53) | F10KDM4EALDH1A1MAPTHPGD | |
| Cadaverine Tartrate SCHEMBL5496172 | 0.91 | F10 (0.55) | F10KDM4EALDH1A1MAPTHPGD | |
| Cadaverine Tartrate SCHEMBL5630923 | 0.90 | F10 (0.55) | F10KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL4835817 | 0.90 | F10 (0.53) | F10KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL4841765 | 0.84 | F10 (0.53) | F10KDM4EALDH1A1MAPTHPGD | |
| Hydrochloric Acid SCHEMBL4832916 | 0.84 | F10 (0.52) | F10KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL4844324 | 0.84 | F10 (0.52) | F10KDM4EALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397348-B1 | FACTOR XA INHIBITOR | LILLY CO ELI (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040162295-A1 | Pharmaceutical compound | ELI LILLY AND COMPANY | 2004-08-19 | — | — | US | claimed |
| EP-1397348-A2 | FACTOR XA INHIBITOR | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | claimed |
| WO-2002100847-A2 | FACTOR XA INHIBITOR | ELI LILLY AND COMPANY (GB) | 2002-12-19 | — | — | WO | claimed |
| US-7351822-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1397348-B1 | FACTOR XA INHIBITOR | LILLY CO ELI (US) | 2005-09-28 | — | — | EP | disclosed |
| US-6946467-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-09-20 | — | — | US | disclosed |
| US-6936611-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1510515-A1 | Phenylglycine derivatives as serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040176363-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-09-09 | — | — | US | disclosed |
| EP-1289972-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040162295-A1 | Pharmaceutical compound | ELI LILLY AND COMPANY | 2004-08-19 | — | — | US | disclosed |
| US-20040142963-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-07-22 | — | — | US | disclosed |
| EP-1397348-A2 | FACTOR XA INHIBITOR | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002100847-A3 | FACTOR XA INHIBITOR | LILLY CO ELI (US) | 2003-08-21 | — | — | WO | disclosed |
| US-20030055246-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-03-20 | — | — | US | disclosed |
| EP-1289972-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2002100847-A2 | FACTOR XA INHIBITOR | ELI LILLY AND COMPANY (GB) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002100847-A2 | FACTOR XA INHIBITOR | ELI LILLY AND COMPANY (GB) | 2002-12-19 | — | — | WO | disclosed |
| WO-2001096323-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055246-A1 | Serine protease inhibitors | CTRL, CPN1, LOXL1 | F10 992/4885KDM4E 3205/4885ALDH1A1 2408/4885 |
| US-20040142963-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | F10 60/4885KDM4E 3503/4885ALDH1A1 2261/4885 |
| US-20040176363-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | F10 60/4885KDM4E 3503/4885ALDH1A1 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.